On this page you can find clinical trials that Ipsen has sponsored and clinical trials that were acquired by Ipsen. You can use the drop-down lists below to find clinical trials by condition, status, phase and country.
Completed clinical trials may also have results available. If so, a simple summary of the overall results can be found on the lay summaries page.
You may also find a scientific summary of the results on the US and EU Clinical Trial Registries.
The ‘status’ of participant recruitment is defined as follows:
- Not yet recruiting – recruitment has not started yet
- Recruiting – recruitment is open
- Enrolling by invitation – recruitment is open to a particular population who are invited to participate.
- Active, not recruiting – recruitment is closed, participants are still ongoing in the clinical trial;
- Terminated – the study stopped early.
- Completed – the study ended.
Last Data Refreshed @ 11-Nov-2026 05:06:16 UTC
Condition
Status
Phase
Country
Showing 1 – 5 of 141 clinical trials
Advanced Solid Tumour
Metastatic Solid Tumour
IPN01203
-
United States of America (the) -
Spain -
France -
Canada
Recruiting
A study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumour activity of IPN01203 in adults with locally advanced or metastatic solid tumours exposed to immune checkpoint inhibitor therapies
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours.
Advanced solid tumours are cancers that can occur in various organs or tissues and have spread from their original site to nearby tissues or other parts of the body.
In this study all participants will receive IPN01203 every 2 weeks. This schedule may be adapted to incorporate stepup dosing (i.e. where treatment starts with a low dose, which is gradually increased over several days or weeks until the full, intended dose is reached), if implemented upon SMC endorsement during phase Ia.
There will be two parts to this study:
Phase Ia: This part (called dose escalation) will find the dose range that shows activity against the tumour and can be tolerated by participants by testing different increasing doses of IPN01203. Phase Ib: This part (called dose optimisation) will assess the ability of the drug to prevent, slow down, or stop the growth of tumours and how the body processes and responds to the drug when given in “low dose” or “high dose.” It will also further explore the safety and tolerability.
An additional part (phase II) may be added to the study based on the results of phase Ia and phase Ib.
Each part will consist of the following periods:
A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre.
A treatment period where all eligible participants will receive IPN01203. Requires approximately 15 visits for the first 2 months followed by 3 visits every month from month 3 until unacceptable toxicity, disease progression, death, upon participant’s withdrawal of consent, investigator decision, or study termination by the sponsor, whichever occurs first.
There will also be one visit at the end of treatment (EoT), 30 days after the last administration of the study intervention or prior to the start of new anticancer treatment, whichever is earlier.
Additionally, there will be one visit (the safety follow-up visit) 90 days after the last administration of study intervention or prior to the start of new anticancer treatment, whichever is earlier.
In both parts of the study, participants will undergo blood sampling, urine collection, physical examinations and clinical evaluations. They may continue some other medications, but the details need to be recorded.
Each participant will be in this study until death or withdrawal from the study. IPN01203 will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.
Chronic Migraine
Episodic Migraine
corabotase
- United States of America (the)
-
United Kingdom of Great Britain and Northern Ireland (the) - Canada
-
Czechia - France
-
Japan -
Germany -
Georgia -
Australia - Spain
-
Brazil -
Poland -
New Zealand -
Korea (the Republic of)
Recruiting
A study to evaluate IPN10200 safety and efficacy in the prevention of episodic or chronic migraine in adults
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head. It is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Migraines are caused by a series of events when the brain gets stimulated or activated, which causes the release of chemicals that cause pain. IPN10200 is a medication that stops the release of these chemical messengers.
Participants with episodic migraine (EM) or chronic migraine (CM) will be included in both Step 1 and Step 2. “Headache days” are when participants experience headaches that meet the criteria for a migraine or a headache without the additional migraine-specific symptoms. “Migraine days” occur when the headache displays clear migraine characteristics.
This study aims to determine:
The safety and efficacy of injecting IPN10200 directly into the muscles of the head and neck to prevent EM and CM,
The right amount (dose) of IPN10200 to inject at each point,
The total amount (dose) of IPN10200 that provides the best balance between safety and efficacy preventing migraines.
Participants will need to complete a daily electronic migraine Diary (eDiary) and questionnaires throughout the study. The total study duration for a participant will be up to 42 weeks.
The study will consist of 3 periods:
A ‘screening period’ to assess whether the participant can take part in the study.
Step 1 is divided in two cohorts. The study will assess sequentially the safety of two doses of IPN10200, a lower dose in the cohort 1 and a higher dose in cohort 2. Participants will be administered with the study drug or placebo. The treatment is injected in muscles of the head, face and neck. The safety of participants is monitored throughout the 36 weeks at each cohort.
Step 2: In this step, new eligible participants will be divided into two groups based on their diagnosis (EM or CM). These groups will then be randomly assigned to one of three intervention groups: Dose A, Dose B, or a placebo. The intervention will be given in a series of injections in muscles of the head, face and neck. Participants will be monitored for both efficacy and safety until they complete the Week 36 visit (the end of study).
Cervical Dystonia
corabotase
- United Kingdom of Great Britain and Northern Ireland (the)
- United States of America (the)
- Poland
- Spain
- Germany
-
Italy - France
- Czechia
Recruiting
A study of IPN10200 for the treatment of cervical dystonia in adults
The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating CD in adults.
Cervical dystonia can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. Cervical dystonia is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role.
The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period.
The study will consist of two periods:
(1) A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit.
(2) A Treatment Period of 36 weeks.
On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck, and shoulders. Participants may continue some other medications, but details need to be recorded. There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study.
The total study duration for a participant will be up to 40 weeks (approximately 9 months).
Primary Biliary Cholangitis (PBC)
Iqirvo
- Brazil
-
Thailand - United States of America (the)
- Spain
-
Peru -
Slovakia -
Romania -
Portugal - New Zealand
- Poland
-
Belgium -
Greece - Korea (the Republic of)
-
Malaysia -
Mexico -
Lithuania - Italy
-
Hungary -
Israel - Australia
-
Argentina -
Denmark - Canada
- Czechia
-
Chile -
Bulgaria -
Colombia - France
Recruiting
A Long-Term Study of Elafibranor in Adult Participants with Primary Biliary Cholangitis
The participants of this study will have confirmed Primary Biliary Cholangitis (PBC) and cirrhosis (scarring).
PBC is a disease that progresses slowly. It causes damage to the bile ducts in the liver, leading to a build-up of bile acids which causes further damage.
The liver damage in PBC may lead to cirrhosis. PBC may also be associated with multiple symptoms. Many people with PBC may require liver transplant or may die if the disease progresses and a liver transplant is not done.
This study will compare a daily dose of elafibranor (the study drug) to a daily dose of placebo (a dummy treatment). Each participant will be in the study for about 3.5 years.
The main aim of this study is to determine if elafibranor is better than placebo in preventing adverse (bad) clinical outcomes including progression of disease leading to liver transplant or death.
This study will also examine the safety of long-term treatment with elafibranor, as well as the impact on symptoms like itching and tiredness.
Primary Sclerosing Cholangitis
Iqirvo
- United States of America (the)
- Spain
- Romania
- Poland
-
Netherlands (Kingdom of the) - Belgium
- Czechia
-
China - France
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC). PSC is a rare disease that causes inflammation and scarring of the bile ducts in the liver. Over time, this can lead to liver damage and serious health problems, including the need for a liver transplant and death.
In this study, about 350 participants with large duct PSC will take part. Participants will be randomized to receive either elafibranor 120 mg once daily or a placebo (a tablet with no active medicine). The study includes a screening period, an treatment period, and a post-treatment safety follow-up.
During the study, participants will undergo routine clinical assessments, laboratory testing, imaging evaluations, and complete patient-reassessments to evaluate liver disease progression, symptoms, quality of life and safety.
Following the end of treatment, participants will complete a safety follow-up period at approximately four weeks. Participants may withdraw from the study at any time. Each participant may be in the study for several years, as the treatment period will continue until the study reaches enough health events among participants, which is expected to take about 5 years.